Internal Medicine · Staten Island, NY
NPI
1255580783
Since 2008
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
1050 Clove Rd
Staten Island, NY, 10301
Phone (718) 816-6440
Groups this clinician bills Medicare through
Medicare paid, 2024
$928K
57,286 services
Medicare patients, 2024
343
Average age 74
Drug cost, 2024
$6.3M
1,410 prescriptions
Company payments, 2025
$1,313
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Efat Azizi was code J1756 (injection, iron sucrose, 1 mg), 13,800 times for 21 patients. In total Efat Azizi billed 57,286 services in 143 codes, and Medicare paid $928K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1756 Injection, iron sucrose, 1 mg | Office | 13,800 | 21 | $0.16 | $2,152 |
| 88185 Surgical Pathology Examination | Office | 989 | 43 | $22.20 | $22K |
| 36415 Venipuncture Blood Collection | Office | 834 | 306 | $8.65 | $7,214 |
| 85025 Blood Count | Office | 788 | 288 | $7.60 | $5,989 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 730 | 14 | $0.09 | $65.26 |
| 80053 Clinical Chemistry | Office | 548 | 256 | $10.31 | $5,651 |
| 99214 Office E&M - Established | Office | 430 | 197 | $100.29 | $43K |
| 83615 Clinical Chemistry | Office | 342 | 189 | $5.92 | $2,025 |
| 84100 Clinical Chemistry | Office | 328 | 172 | $4.62 | $1,516 |
| 83735 Clinical Chemistry | Office | 325 | 171 | $6.51 | $2,116 |
| 84550 Clinical Chemistry | Office | 319 | 168 | $4.42 | $1,409 |
| 82784 Immunoassay | Office | 255 | 64 | $9.11 | $2,324 |
| 83550 Clinical Chemistry | Office | 240 | 150 | $8.53 | $2,048 |
| 83540 Clinical Chemistry | Office | 239 | 150 | $6.31 | $1,509 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 239 | 69 | $51.77 | $12K |
By year: 2022 $472K for 50,998 services; 2023 $445K for 41,322 services; 2024 $928K for 57,286 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88185 Surgical Pathology Examination | 989 | 43 | $22.20 | $22K |
| 36415 Venipuncture Blood Collection | 834 | 306 | $8.65 | $7,214 |
| 85025 Blood Count | 788 | 288 | $7.60 | $5,989 |
| 80053 Clinical Chemistry | 548 | 256 | $10.31 | $5,651 |
| 83615 Clinical Chemistry | 342 | 189 | $5.92 | $2,025 |
| 84100 Clinical Chemistry | 328 | 172 | $4.62 | $1,516 |
| 83735 Clinical Chemistry | 325 | 171 | $6.51 | $2,116 |
| 84550 Clinical Chemistry | 319 | 168 | $4.42 | $1,409 |
| 82784 Immunoassay | 255 | 64 | $9.11 | $2,324 |
| 83550 Clinical Chemistry | 240 | 150 | $8.53 | $2,048 |
Medicare prescription drug claims, 2024
In 2024, the drug Efat Azizi prescribed most often to Medicare patients was Anastrozole, with 203 prescriptions and refills. In total Efat Azizi wrote 1,410 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 203 | 552 | 77 | $3,850 |
| Xtandi Enzalutamide | 105 | 109 | 20 | $1.5M |
| Aranesp Darbepoetin Alfa In Polysorbat | 89 | 89 | 34 | $301K |
| Xgeva Denosumab | 54 | 63 | 17 | $166K |
| Lupron Depot Leuprolide Acetate | 52 | 148 | 21 | $285K |
| Prednisone Generic | 51 | 62 | 14 | $199 |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 51 | 51 | Under 11 | $633K |
| Abiraterone Acetate Generic | 46 | 56 | Under 11 | $128K |
| Hydroxyurea Generic | 42 | 95 | 13 | $1,320 |
| Revlimid Lenalidomide | 38 | 38 | Under 11 | $603K |
| Eliquis Apixaban | 37 | 80 | 15 | $45K |
| Akynzeo Fosnetupitant/Palonosetron | 37 | 37 | 11 | $34K |
| Procrit Epoetin Alfa | 33 | 33 | 15 | $104K |
| Neulasta Onpro Pegfilgrastim | 31 | 31 | Under 11 | $185K |
| Letrozole Generic | 28 | 68 | Under 11 | $394 |
Brand drugs: 751 claims; generic drugs: 659 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Efat Azizi $1,313 ($1,313 in general payments such as food, travel and fees) from 8 companies. The largest payer was Gilead Sciences, Inc. with $556.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.